The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Genentech announced new clinical and real-world data on its anti-CD20 therapy Ocrevus (ocrelizumab) at the 9th Joint ECTRIMS-ACTRIMS Meeting (European and Americas Committees for Treatment and Research in Multiple Sclerosis) that it said “continue to deepen our understanding of multiple sclerosis (MS).” 12 October 2023
Danish allergy immunotherapy specialist ALK Abello today announced positive top-line results from a Phase III pediatric clinical trial of its sublingual allergy immunotherapy tablet for the treatment of tree-pollen-induced allergic rhinoconjunctivitis. 11 October 2023
A new product from French pharma major Sanofi’s Indian subsidiary, Soliqua (insulin glargine and lixisenatide recombinant fixed-dose combination), has recently been granted approval by the Central Drugs Standard Control Organization (CDSCO). 11 October 2023
Patrick Branch, a Japan-based strategy consultant from LEK Consulting, provides an Expert View on the ‘new map’ for healthcare firms in Asia. 11 October 2023
Swedish company Egetis Therapeutics has raised around $16 million in a private share placement led by US healthcare investor Frazier Life Sciences. 11 October 2023
UK clinical-stage biotech PureTech Health has presented new clinical data supporting the differentiated profile of LYT-100 (deupirfenidone) at the CHEST Annual Meeting in Honolulu, Hawaii. 11 October 2023
Danish biotech MinervaX, a privately held firm working on a novel, prophylactic vaccine against Group B Streptococcus (GBS), has raised $57 million from a range of new and existing sources of finance. 11 October 2023
Danish diabetes care giant Novo Nordisk saw its shares rise 3.7% to 673.90 kroner today, on positive news announced to the stock exchange late on Tuesday. 11 October 2023
With the aim of advancing its fibrosis-focused pipeline, Belgian biotech Agomab Therapeutics today announced the closing of a $100 million (94.9 million euros) Series C financing. 11 October 2023
Samsung Bioepis, a business of South Korea-based Samsung BioLogics has outlined data it is presenting at the ongoing congress of the European Academy of Dermatology and Venereology (EADV). 11 October 2023
Small molecule drugs are carving a significant niche in lung cancer treatment, an area in which AstraZeneca achieved a landmark approval from the US Food and Drug Administration (FDA) following the results of the Phase III AURA trial. 11 October 2023
BioMap today announced a ground-breaking strategic collaboration with French pharma major Sanofi to co-develop cutting-edge artificial intelligence (AI) modules for biologic therapies leveraging BioMap’s AI platform. 11 October 2023
Lifera, a biopharmaceutical company wholly-owned by the Saudi Arabian Public Investment Fund (PIF), says it has successfully completed its acquisition of a 70% stake in SaudiBio. 11 October 2023
Johnson & Johnson’s Janssen subsidiary has submitted a Type II variation application to the European Medicines Agency (EMA) seeking approval of a new indication for Rybrevant (amivantamab). 10 October 2023
In the USA, the National Institutes of Health has outlined significant new investments to support research into amyotrophic lateral sclerosis (ALS). 10 October 2023
US clinical-stage biotech Akero Therapeutics saw its shares slump 59% to $48.44, after it released new data Phase IIb data on its lead product candidate efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to non-alcoholic steatohepatitis (NASH), joining a string of companies failing in their attempts in this therapy area. 10 October 2023